Fig. 5: OV-monocyte interactions promote CD8 + T cell recruitment.
a Tumor measurements for untreated CT26LacZ-bearing animals and mice treated with two doses of VSV-FLUC (106 PFU, 48 h between i.v. injections) ±anti-CD8 treatment. Results are shown as mean ± SEM (n = 6 for untreated group; n = 8 for VSV-treated groups); two-way ANOVA followed by Sidak’s multiple comparisons test. b Kaplan-Meier survival plots for the groups shown in a; log-rank test. c Luminescence intensity for CT26LacZ tumors following a 2-dose OVT treatment schedule (106 PFU VSV-FLUC, 48 h between doses) ± CD8 depletion. Results are shown as mean with individual values (n = 6); two-way ANOVA. d Representative bioluminescent images for groups shown in c 24 h post second virus injection. e FC analysis of tumor CD8 + cells 72 h following a single VSV dose or 24 h post second VSV dose (106 PFU) ± anti-CCR2 or CLL treatment 24 h after initial virus administration. Results are shown as percentage of CD45 + cells and plotted as mean ± SEM (one-way ANOVA followed by Tukey’s multiple comparisons test). f Representative IVM images of tumor vessels and leukocytes at 72 h following a single VSV dose or 24 h post second VSV dose ± anti-CCR2 treatment 24 h after initial virus administration. Green, neutrophils; red, monocytes; blue, CD8 + cells. Vessels counterstained by Qtracker 655 (gray); scale bar, 50 µm. g IVM analysis of CD8 + cells in CT26LacZ tumors 72 h following a single VSV dose or 24 h post second VSV dose (106 PFU) ± anti-CCR2 treatment 24 h after initial virus administration. Results are shown as CD8 + cell counts per mm2 and plotted as mean ± SEM (one-way ANOVA followed by Tukey’s multiple comparisons test).
